GLP-1 receptor agonists mimic the action of the glucagon-like peptide-1 hormone, which is involved in the regulation of ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...

The study analyzed electronic health records from 708,406 patients diagnosed with breast cancer between January 2011 and ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

A recent study points to a potential link between GLP-1 drugs and its ability to reduce risk of epilepsy in people with type 2 diabetes. GLP-1 drugs (semaglutide) are those which mimic the function of ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Food-packed tables and endless spirits can present a special challenge for those taking GLP-1 medications like Wegovy, ...

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

GLP-1 receptor agonists are associated with a lower risk of dementia than DPP-4 inhibitors in dialysis patients with diabetes.

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described compounds acting as gastric inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR) and ...

Topline phase 3 results show retatrutide led to meaningful weight reduction and pain relief in adults with overweight or obesity and knee OA.